image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Our latest issue will be released in 10 days, don't miss out!

Playtech - EBITDA approaching normalised levels

October 2020

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • PTEC
  • Price:
  • 369p
The highlight of gaming software and services group Playtech’s trading update on 5 August was a “strong performance in July” with EBITDA approaching “normalised levels,” which broker Jefferies takes to mean c. Eu30m per month, using results from 2019.Adjusted EBITDA of Eu160m is guided for H1. It would only need to generate c. Eu120m to meet current consensus forecasts of Eu281m but momentum is such that this could be exceeded, says Jefferies.In B2B gaming, H1 20 was very strong with Bingo and Poker benefiting from people staying at home during lockdown and although this is now normalising to historic levels (as movement restrictions have eased), it is still tracking above pre-Covid levels. The sports side is heavily weighted ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author